These data suggest that pharmacological treatment of AF may be improved by assessing for a defect in the TBX5-SERCA2-PLN axis followed by specifically targeting the defect to restore normal cardiomyocyte electrical activity. This evidence concerns the gene ATP2A2 and atrial fibrillation.